- Home
- CFR
as 11-04-2025 3:57pm EST
Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
| Founded: | 1868 | Country: | United States |
| Employees: | N/A | City: | SAN ANTONIO |
| Market Cap: | 8.1B | IPO Year: | N/A |
| Target Price: | $138.44 | AVG Volume (30 days): | 463.0K |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 9.72 | EPS Growth: | 20.47 |
| 52 Week Low/High: | $100.31 - $147.64 | Next Earning Date: | 10-30-2025 |
| Revenue: | $2,141,575,000 | Revenue Growth: | 9.02% |
| Revenue Growth (this year): | 13.32% | Revenue Growth (next year): | 4.19% |
Latest Cullen/Frost Bankers Inc. News
CFR Breaking Stock News: Dive into CFR Ticker-Specific Updates for Smart Investing
Zacks
a month ago
FHN vs. CFR: Which Stock Is the Better Value Option?
Zacks
a month ago
Are You Looking for a High-Growth Dividend Stock?
Zacks
a month ago
FHN vs. CFR: Which Stock Should Value Investors Buy Now?
Zacks
4 months ago
This is Why Cullen/Frost Bankers (CFR) is a Great Dividend Stock
Argus Research
4 months ago
CFR: Raising target price to $133.00
StockStory
4 months ago
CFR Q1 Deep Dive: Expansion Drives Growth Amid Deposit and Loan Momentum
Zacks
5 months ago
Zacks.com featured highlights include StoneCo, Cullen/Frost Bankers, Intuit and The Mosaic
Simply Wall St.
5 months ago
Cullen/Frost Bankers (NYSE:CFR) Ticks All The Boxes When It Comes To Earnings Growth
Compare CFR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CFR Cullen/Frost Bankers Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.